Pacific Edge says it isn't out of the game in the US, it's at the midway point of the match

Pacific Edge says it isn't out of the game in the US, it's at the midway point of the match
To be or not to be in Medicare? That's the question facing NZX-listed Pacific Edge. (Image: Pacific Edge)
Rebecca Stevenson
The head of listed cancer diagnostics company Pacific Edge says its singular focus on the United States market is not a single point of failure. Pacific Edge’s share price has taken a hammering after it announced earlier this year it could lose access to the US Medicare system after Novitas – which administers Medicare – determined the Dunedin-based company’s products did not meet new thresholds for coverage under the US Social Security Act. On Monday, its shares were again buffeted by negative news when the US...

More Markets

NZ sharemarket up 0.5% ahead of long weekend
Markets Market Close

NZ sharemarket up 0.5% ahead of long weekend

Pacific Edge's share price fell 7.32%.

Tom Raynel 24 Apr 2025
Pacific Edge suffers another setback in US
Markets

Pacific Edge suffers another setback in US

Shares in cancer diagnostics company Pacific Edge are down 2.44% to $0.120 after another setback in the US market.The US District Court for the Middle District of Pennsylvania has determined that it does not have jurisdiction to review a Local Coverage Determination (LCD) that co...

Staff reporters 24 Apr 2025
Listed retailers stand to gain from Trump tariffs:  Forsyth Barr
Retail

Listed retailers stand to gain from Trump tariffs: Forsyth Barr

Forsyth Barr lifted its KMD Brands target price by 10.4% after Trump tariff walkbacks.

Gregor Thompson 24 Apr 2025
NZ sharemarket rises as Trump backs down
Markets Market Close

NZ sharemarket rises as Trump backs down

The S&P/NZX 50 Index closed up 1.01% or 119.78 points.

Tom Raynel 23 Apr 2025